Table 2.

Markers significantly associated with PFS under ICI in the discovery cohort YTMA471; Progression Free Survival, PFS; Immune Checkpoint Inhibitors, ICI; Yale tissue microarray, YTMA; AOI, Area of Illumination

MARKERS ASSOCIATED WITH PFS
Compartment/AOI	N	Marker	Univariate HR (95% CI)	P-value	Multivariate HR (95% CI)	P-value
CK (panCK+)	54	PD-L1	0.67 (0.48, 0.94)	0.017	0.50 (0.36, 0.71)	0.002
		EpCAM	1.48 (1.17, 1.88)	<0.001	1.37 (1.08, 1.73)	0.02
		Tim-3	0.63 (0.42,0.94)	0.024	0.61 (0.39, 0.95)	0.056
		CD66b	1.19 (1.02,1.38)	0.039	1.29 (1.11,1.51)	0.009
		CD44	0.76 (0.61, 0.96)	0.024	0.63 (0.50, 0.80)	0.002
Immune Stroma (panCK−/CD45+/CD68+)	54	S100B	0.64 (0.47, 0.87)	0.003	0.66 (0.48, 0.90)	0.024
		EpCAM	1.4 (1.12, 1.82)	0.004	1.40 (1.09, 1.80)	0.046
		CD66b	1.24 (1.02, 1.51)	0.040	1.31 (1.08, 1.58)	0.023
		FOXP3	1.54 (1.03, 2.31)	0.045	1.33 (0.87, 2.02)	0.3
CD45 (panCK−/CD45+/CD68−)	52	PD-L1	0.52 (0.32, 0.84)	0.008	0.47 (0.29, 0.75)	0.007
		S100B	0.63 (0.46, 0.86)	0.002	0.61 (0.44, 0.84)	0.011
		CD14	0.63 (0.40, 0.98)	0.037	0.58 (0.37, 0.93)	0.037
CD68 (panCK−/CD68+)	49	S100B	0.69 (0.50, 0.95)	0.018	0.74 (0.50,1.08)	0.12
		EpCAM	1.42 (1.12,1.81)	0.004	1.49 (1.08, 2.05)	0.015
		MART1	1.73 (1.08,2.76)	0.021	2.25 (1.11, 4.56)	0.016
		P44/42 MAPK ERK1/2	0.40 (0.17, 0.92)	0.040	0.47 (0.19, 1.18)	0.12
		CD66b	1.28 (1.05, 1.56)	0.019	1.39 (1.12, 1.73)	0.004
		FOXP3	1.67 (1.12,2.48)	0.018	2.03 (1.16, 3.56)	0.013

Note: Bold terms have P values that are significant after adjusting for multiple comparisons and/or after controlling for clinical prognostic factors in the multivariate analysis. Progression-free survival (PFS) was calculated from the start of immunotherapy until progression of disease, death, or censoring.